Form 10-K · Annual report
Bio-Techne 10-K, filed Aug 24, 2026
- Filed
- CIK
- 0000842023
- Accession no.
- 0001104659-26-100322
Summary
Bio-Techne reported flat fiscal 2026 net sales of $1.2 billion and a 148% rise in consolidated net earnings, while its pending merger with Merck KGaA would give shareholders $73.00 per share in cash. The merger is expected to close by late 2026 or early 2027, subject to shareholder and regulatory approvals.
Key points
- Bio-Techne entered a merger agreement with Merck KGaA on June 25, 2026, under which a Merck subsidiary will merge into Bio-Techne and Bio-Techne will survive as a wholly owned Merck subsidiary.
- Each outstanding Bio-Techne share will convert into the right to receive $73.00 in cash.
- Fiscal 2026 consolidated net sales were flat at $1.2 billion, with organic revenue flat and foreign currency translation providing a 2% favorable impact.
- Consolidated net earnings rose 148% in fiscal 2026, while adjusted net earnings decreased 1%; Protein Sciences net sales rose 1% and Diagnostics and Spatial Biology net sales fell 3%.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
ITEM 7. MANAGEMENT’S DISCUSSION OVERVIEW Bio-Techne develops, manufactures and sells life science reagents, instruments and services for the research and clinical diagnostic markets worldwide. With our deep product portfolio and application expertise, we sell integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. Our products aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. We manage the business in two operating segments – our Protein Sciences segment and our Diagnostics and Spatial Biology segment. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.